Муковисцидоз: определение, диагностические критерии, терапия. Национальный консенсус

28. Shibl A. Effect of antibiotics on production of enzymes and toxins by microorganisms. Rev. Infect. Dis. 1983; 5: 865–75.

29. Dalhoff A., Doеring G. Interference of ciprofloxacin with the expression of pathogenicity factors of Pseudomonas aeruginosa. In: Adam D., Hahn H., Opferkuch W., eds. The Influence of Antibiotics on the Host-parasite Relationship II. Berlin: Springer, 1985: 246–55.

30. Regaard A.R., Bjuro K., Bukholm G., Berdal B.P. Pseudomonas aeruginosa virulence factors: modifications by subinhibitory concentrations of carbenicillin or gentamycin. Acta Path. Microbiol. Immunol. Scand. 1986; 94: 63–8.

31. Cantin A.M., Woods D.E. Protection by antibiotics against myeloperoxidase-dependent cytotoxicity to lung epithelial cells in vitro. J. Clin. Invest. 1993; 91: 38–45.

32. Barclay M.L., Begg E.J., Chambers S.T., et al. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis. J. Antimicrob. Chemother. 1996; 37: 1155–64.

33. Mann H.J., Canafax D.M., Cipolle R.J., et al. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis. Pediatr. Pulmonol. 1985; 1: 238–43.

34. De Groot R., Hack B.D., Weber A., et al. Pharmacokinetics of ticarcillin in patients with cystic fibrosis: a controlled prospective study. Clin. Pharmacol. Ther. 1990; 47: 73–8.

35. De Groot R., Smith A.L. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clin. Pharmacokinet. 1987; 13: 228–53.

36. Horrevorts A.M, de Witte J., Degener J.E., et al. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. Chest. 1987; 92: 844–8.

37. Stutman H.R., Shalit I., Marks M.I., et al. Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. Am. J. Med. 1987; 82: 142–5.

38. Prandota J. Drug disposition in cystic fibrosis: progress in understanding pathophysiology and pharmacokinetics. Pediatr. Infect. Dis. 1987; 6: 1111–26.

39. Szaff M., Hoiby N., Flensborg E.W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediat. Scand. 1983; 72: 651–7.

40. Lee T.W., Brownlee K.G., Conway S.P., et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2003; 2: 29–34.

41. Proesmans M., Balinska-Miskiewicz W., Dupont L., et al. Evaluating the «Leeds criteria» for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur. Respir. J. 2006; 27: 937–43.

42. Ratjen F., Doring G., NiKolaizik W.H. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonization in patients with cystic fibrosis. Lancet. 2001; 358 (9286): 983–4.

43. Mayer-Hamblett N., Kronmal R.A., Gibson R.L., et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerdations in cystic fibrosis. Pediatr. Pulmonol. 2012; 47 (2): 125–34.

44. Marchetti F., Giglio L., Candusso M., et al. Early antibiotic treatment of Pseudomonas aeruginosa colonization in cystic fibrosis: a critical review of the literature. Eur. J. Clin. Pharmacol. 2004; 60: 67–74.

45. Clinical Guidelines: Care of Children with Cystic Fibrosis. Royal Brompton Hospital, 2014. www.rbht. nhs.uk/childrencf (дата обращения: 10.06.2014).

46. Cystic Fibrosis in children and adults. The Leeds Method of Management. November 7, 2008, St. James’s University Hospital, UK.

47. Hodson M.E., Roberts C.M., Butland R.J., et al. Oral ciprofloxacin compared with conventional intravenous treatment Pseudomonas aeruginosa infection in adult with cystic fibrosis. Lancet. 1987; 1: 235–7.

48. Shalit I., Stutman H.R. Marks M.I., et al. Randomized study of two dosage regimens of ciprofloxacin for treating chronic bronchopulmonary infection in patients with cystic fibrosis. Am. J. Med. 1987; 82: 189–95.

49. Church D.A., Kanga J.F., Kuhn R.J., et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. Ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group. Pediatr. Infect. Dis. J. 1997; 16: 97–105.

50. Schaad U.B., Wedgwood-Krucko J., Guenin K., et al. Antipseudomonal therapy in cystic fibrosis: aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 1989; 8: 858–65.

51. Frederiksen B., Koch C., Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 1997; 23: 330–5.

52. Ramsey B.W., Pepe M.S., Quan J.M., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 1999; 340: 23–92.

53. Knowles M.R., Robinson J.M., Wood R.E., et al. Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease control subjects. J. Clin. Invest. 1997; 100: 2588–95.

54. Konstan M.W., Flume P.A., Kappler M., et al. Safety, eficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. Journal of Cystic Fibrosis. 2011; 10 (1): 54–61.

55. Littlewood J.M., Miller M.G., Ghoneim A.T., Ramsden C.H. Nebulised colomycin for early Pseudomonas colonization in cystic fibrosis. Lancet. 1985; 1: 865.

56. MacLusky I., Gold R., Corey M., Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr. Pulmonol. 1989; 7: 42–8.

57. Valerius N.H., Koch C., Hoiby N. Prevention of chronic Pseudomonas aeruginosa Antibiotic treatment of initial colonization with postpones infection and prevent deterioration of pulmonary function in cystic fibrosis by early treatment. Lancet. 1991; 338 (8769): 725–6.

58. Ryan G., Singh M.K.D. Inhaled antibiotics for longterm therapy in cystic fibrosis. Cochrane Database Syst Rev. 2011; Issue 3. Art. No.: CD001021. DоI: 10.1002/14651858. CD001021.pub2.

59. Hoiby N. Pseudomonas in Cystic Fibrosis: past, present, future. The Fourth Joseph Levy Lecture. Cystic Fibrosis Trust, Berlin, June 1998: 1–25.

60. Taccetti G., Bianchini E., Cariani L., et al. Early antibiotic treatment for Pseudomonas aeruginosae radicationin patients with cystic fibrosis: a randomized multicentre study comparing two different protocols. Thorax. 2012; 67 (10): 853–59.

61. Hansen C.R., Pressler T., Hoiby N. Early aggressive eradication therapy for interrmittent Pseudomonas aeruginosa colonizationin cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 2008; 7 (6): 523–30.

62. Wiesemann H.G., Steinkamp G., Ratjen F., et al. Placebocontrolled, double-blind, randomized study of aerolized tobramycin for early treatment of Pseudomonas aeruginosa infection in cystic fibrosis. Pediatr. Pulmonol. 1998; 25: 88–92.

63. Gibson R.L., Emerson J., McNamara S., et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167 (6): 841–9.

64. Langton-Hewer S.C., Smyth A.R. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2006: Issue 4. Art. No.: CD004197 (updated 2010) DOI:10.1002/14651858.CD004197. pub3.

65. Treggiari M.M., Retsch-Bogart G., Mayer-Hamblett N., et al. Comparative eficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch. Pediatr. Adolesc. Med. 2011; 165: 847–56.

66. Gibson R.L., Emerson J., Mayer-Hamblett N., et al. Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr. Pulmonol. 2007; 42: 610–23.

67. Proesmans M., Vermeulen F., Boulanger L., et al. Comparison of two treatment regimens for eradication of P. аeruginosa infection in children with cystic fibrosis. J. Cyst. Fibros. 2013; 12 (1): 29–34.

68. Rosenfeld M., Gibson R., McNamara S., et al. Serum and lower respiratory tract drug concentrations produced by tobramycin for inhalation in young children with cystic fibrosis J. Pediatr. 2001; 139: 572–7.

69. Marchetti F., Giglio L., Candusso M., et al. Early antibiotic treatment of Рseudomonas aeruginosa colonization in cystic fibrosis: a critical review of the literature. European Journal of Clinical Pharmacology. 2004; 60 (2): 67–4.

70. Sordе R., Pahissa A., Rello J. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infect. Drug Resistance. 2011; 4: 31–41.

71. Koch C., Hоiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 1997; 23: 330–5.

72. Jensen T., Pedersen S.S., Garne S., et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J. Antimicrob. Chemother. 1987; 19: 831–38.

73. Jensen T., Pedersen S.S., Hoiby N., Koch C. Eficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis. Eur. J. Clin. Microbiol. 1987; 6: 618–22.

74. Jensen T., Pederson S.S., Hoiby N., et al. Use of antibiotics in cystic fibrosis: the Danish approach. Antibiot. Chemother. 1989; 42: 237–46.

75. Amelina E., Cherniak A., Krasovsky S. Burkholderia cepacia infection in adult cystic fibrosis patients: its impact on lung function and survival. Abstracts 20th ERS Annual Congress. Spain, Barcelona, September 18–22, 2010. Eur. Respir. J. 2010; 36 (Suppl. 54): 885s: 4807.

76. Sousa S.A., Ramos C.G., Leitаo J.H. Burkholderia cepacia сomplex: Emerging Multihost Pathogens Equipped with a Wide Range of Virulence Factors and Determinants. Int. J. Microbiol. 2011; 2011. Pii: 607575. Doi: 10.1155/2011/607575. Epub 2010 Aug 3.

77. Воронина О.Л., Чернуха М.Ю., Шагинян И.А. и др. Характеристика генотипов штаммов Burkholderia cepacia complex, выделенных от больных в стационарах Российской Федерации. Молекулярная генетика. 2013; 2: 22–30.